Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors

April 26, 2022

It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors, according to Nicole Faust, CEO and chief science officer of Cevec Pharmaceuticals. Faust talked to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in Barcelona, Spain.

Upscaling the production of AAV vectors is "not an easy task," Faust said. She chaired a session on tackling the global shortage of viral vectors on day one of the meeting.

"A lot of people are trying to improve the system," she said. "Another challenge is that the quality of AAV vectors that is going to be produced is going to be really variable."

Faust also highlighted the need for Europe to focus more on opportunities than risks to remain competitive in the market for advanced therapy medicinal products.

Click on the video below to learn more.


Meeting on the Med opens with new data and eyes on the money
BARCELONA, SPAIN -- The Cell & Gene Meeting on the Med conference kicked off on April 20 as speakers assessed the current state of the cell and gene therapy...

Copyright © 2022 scienceboard.net

Last Updated bc 4/25/2022 12:51:32 PM